Evidence map›Paper›PMID 37140929›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.

Bahar Rastegar, Natalie Andersson, Alexandra Petersson, Jenny Karlsson, Subhayan Chattopadhyay, Anders Valind, Caroline Jansson, Geoffroy Durand, Patrik Romerius, Karin Jirström and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Bahar RastegarDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0009-0000-8127-9055
Natalie AnderssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-3643-4404
Alexandra PeterssonDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-5574-9217
Jenny KarlssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0001-7681-0059
Subhayan ChattopadhyayDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-8599-2971
Anders ValindDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-1654-6978
Caroline JanssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0009-0001-4115-0414
Geoffroy DurandDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0001-9004-7248
Patrik RomeriusDepartment of Pediatrics, Skåne University Hospital, Lund, Sweden.ORCID 0009-0000-4651-4734
Karin JirströmDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0003-2257-5000
Linda Holmquist MengelbierDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-3632-2760
David GisselssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-0301-426X
Lund University · SESkåne University Hospital · SE

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation)Cancerfonden (Swedish Cancer Society)EU Interreg Grant (iCOPE)Vetenskapsrådet (VR)
6 · The paper itself

Abstract

purposeWhile patients with intermediate-risk (IR) Wilms tumors now have an overall survival (OS) rate of almost 90%, those affected by high-stage tumors with diffuse anaplasia have an OS of only around 50%. We here identify key events in the pathogenesis of diffuse anaplasia by mapping cancer cell evolution over anatomic space in Wilms tumors. EXPERIMENTAL

designWe spatially mapped subclonal landscapes in a retrospective cohort of 20 Wilms tumors using high-resolution copy-number profiling and TP53 mutation analysis followed by clonal deconvolution and phylogenetic reconstruction. Tumor whole-mount sections (WMS) were utilized to characterize the distribution of subclones across anatomically distinct tumor compartments.

resultsCompared with non-diffuse anaplasia Wilms tumors, tumors with diffuse anaplasia showed a significantly higher number of genetically distinct tumor cell subpopulations and more complex phylogenetic trees, including high levels of phylogenetic species richness, divergence, and irregularity. All regions with classical anaplasia showed TP53 alterations. TP53 mutations were frequently followed by saltatory evolution and parallel loss of the remaining wild-type (WT) allele in different regions. Morphologic features of anaplasia increased with copy-number aberration (CNA) burden and regressive features. Compartments demarcated by fibrous septae or necrosis/regression were frequently (73%) associated with the emergence of new clonal CNAs, although clonal sweeps were rare within these compartments.

conclusionsWilms tumors with diffuse anaplasia display significantly more complex phylogenies compared with non-diffuse anaplasia Wilms tumors, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.

Indexed as

Kidney NeoplasmsWilms TumorAnaplasiaHumansPhylogenyRetrospective Studies

Identifiers

PMID37140929
PMCPMC10345961
OpenAlexW4368358939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.